Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been given an average recommendation of “Buy” by the thirteen analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $88.00.

JANX has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush reiterated an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $30.22 on Thursday. The firm has a market cap of $1.79 billion, a P/E ratio of -25.83 and a beta of 3.23. The business’s 50 day moving average price is $40.83 and its 200-day moving average price is $47.40. Janux Therapeutics has a fifty-two week low of $29.51 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, equities analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Insider Buying and Selling

In other news, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the sale, the chief executive officer now directly owns 217,054 shares of the company’s stock, valued at approximately $12,196,264.26. This represents a 10.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now directly owns 9,658,988 shares of the company’s stock, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 50,002 shares of company stock worth $2,684,703. Insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in JANX. RA Capital Management L.P. raised its position in Janux Therapeutics by 13.1% during the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company’s stock worth $554,977,000 after buying an additional 1,200,000 shares during the last quarter. Paradigm Biocapital Advisors LP raised its holdings in Janux Therapeutics by 46.5% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company’s stock worth $188,246,000 after purchasing an additional 1,115,412 shares in the last quarter. Janus Henderson Group PLC lifted its position in Janux Therapeutics by 41.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock valued at $190,617,000 after purchasing an additional 1,038,996 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in Janux Therapeutics by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock valued at $163,926,000 after purchasing an additional 986,750 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Janux Therapeutics by 596.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company’s stock worth $59,429,000 after purchasing an additional 950,557 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.